Novo Nordisk, Sanofi and Eli Lilly are facing racketeering charges in the US over their insulin prices.
The case is being adjudicated at a court in New Jersey, Fiercepharma reports.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.